|Invitrogen||Applera's Applied Biosystems||$6.7B merger|| |
Invitrogen has agreed to acquire all of the shares of Applera's Applied Biosystems in a $6.7 billion cash and stock deal. The companies are two of the biggest suppliers to the drug development business.
|Roche||ThromboGenics and BioInven||$774M deal|| |
In the deal, ThromboGenics gets a whopping $77.4 million upfront payment from Roche, with close to $700 million in milestones that will be split 60/40 between ThromboGenics and BioInvent.
|Boehringer Ingelheim||Actimis Pharmaceuticals||$515M buyout|| |
Boehringer is buying Actimis Pharmaceuticals, which is developing asthma and allergy drugs.
|Kyowa Hakko||Alnylam Pharmaceuticals||$93M development pact|| |
Cambridge, MA-based Alnylam will develop an Respiratory Syncytial Virus therapy for Asian markets.
|Parexel||ClinPhone||$182M buyout|| |
CRO Parexel has made a $182 million bid for U.K.-based ClinPhone, but it may be facing competition from Quintiles, the world's largest private CRO.
|Stiefel Laboratories||Barrier Therapeutics||$148M buyout|| |
Barrier Therapeutics is a developer of dermatology products.
Roche inks $774M pact